Tirzepatide Peptide

Tirzepatide Peptide

Tirzepatide is a novel dual agonist of the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). This dual incretin receptor agonism represents a significant advancement in metabolic wellness, as it simultaneously activates two complementary incretin pathways that together produce metabolic effects exceeding those of selective GLP-1R agonism alone.

How It Works

Tirzepatide's dual receptor agonism engages complementary metabolic pathways:

**GIP Receptor (GIPR) Activation:**

• Stimulates glucose-dependent insulin secretion, promotes beta-cell health, and modulates adipocyte lipid metabolism

• May contribute to appetite regulation and energy expenditure modulation through central GIPR signaling

**GLP-1 Receptor (GLP-1R) Activation:**

• Stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and activates central satiety circuits

**Synergistic Dual Agonism:**

• Simultaneous GIPR and GLP-1R activation produces greater reductions in food intake, body weight, and blood glucose than either receptor alone

Key Benefits

• Superior Appetite Control:: Dual receptor activation produces more powerful appetite suppression than single-receptor agonists

• Weight Management:: Supports significant body weight reduction through complementary mechanisms

• Metabolic Health:: Supports healthy glucose metabolism and insulin function

• Body Composition:: Supports favorable changes in fat mass and lean mass

Structural Properties

Tirzepatide has a molecular weight of 4813.5 Da (CAS: 2023788-19-2). A 39-amino acid peptide with a C20 fatty diacid chain enabling albumin binding and extended half-life. Purity ≥98.0%.

Quality and Purity

Supplied as a lyophilized powder with purity ≥98.0% verified by HPLC and mass spectrometry. Each vial contains 5 mg.

Storage

Store at −20°C. Stable for 24 months.